Advertisement

Partnership Points to New Path Forward For Drug Approval and Clinical Research 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Registration Trial Design

Lung-MAP is designed to provide a fast, efficient path to full approval, said Roy Herbst, co-chair of the trial’s steering committee and co-chair of its executive operations group. The idea is to get drugs to patients throughout the community, going seamlessly from a phase II portion to phase III, with all patients counting toward registration.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement